Syndax Pharmaceuticals, Inc. (SNDX)
Largest Insider Buys in Sector
SNDX Stock Price History Chart
SNDX Stock Performance
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Insider Activity of Syndax Pharmaceuticals, Inc.
Over the last 12 months, insiders at Syndax Pharmaceuticals, Inc. have bought $25,037 and sold $3.74M worth of Syndax Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Syndax Pharmaceuticals, Inc. have bought $251,151 and sold $12.76M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Goldan Keith A. (Chief Financial Officer) — $50,075.
The last purchase of 1,250 shares for transaction amount of $25,037 was made by Goldan Keith A. (Chief Financial Officer) on 2024‑06‑14.
List of Insider Buy and Sell Transactions, Syndax Pharmaceuticals, Inc.
| 2024-06-14 | Goldan Keith A. | Chief Financial Officer | 1,250 0.0015% | $20.03 | $25,037 | -2.19% | ||
| 2023-08-09 | Sale | Morrison Briggs | director | 52,855 0.0754% | $18.27 | $965,402 | +7.61% | |
| 2023-08-02 | Sale | Meury William | director | 83,000 0.12% | $20.46 | $1.7M | -2.10% | |
| 2023-07-10 | Sale | Morrison Briggs | director | 52,855 0.0766% | $20.40 | $1.08M | 0.00% | |
| 2023-06-13 | Sale | Goldan Keith A. | Chief Financial Officer | 577 0.0008% | $22.31 | $12,873 | -8.20% | |
| 2023-06-09 | Sale | Morrison Briggs | director | 52,855 0.0762% | $21.18 | $1.12M | -2.88% | |
| 2023-05-09 | Sale | Morrison Briggs | director | 52,855 0.0754% | $21.41 | $1.13M | -3.89% | |
| 2023-04-10 | Sale | Morrison Briggs | director | 52,855 0.0768% | $19.53 | $1.03M | +5.79% | |
| 2023-03-13 | Sale | Morrison Briggs | 52,854 0.0765% | $22.53 | $1.19M | -9.01% | ||
| 2023-02-15 | Sale | Ordentlich Peter | 17,428 0.025% | $25.84 | $450,404 | -21.55% | ||
| 2023-02-06 | Sale | Morrison Briggs | 52,854 0.077% | $26.83 | $1.42M | -23.14% | ||
| 2023-02-06 | Sale | Metzger Michael A | 5,959 0.0089% | $27.64 | $164,697 | -23.14% | ||
| 2023-02-01 | Sale | Ordentlich Peter | 69 <0.0001% | $28.43 | $1,962 | -29.64% | ||
| 2023-01-13 | Sale | Legault Pierre | director | 5,000 0.0074% | $27.00 | $135,000 | -22.23% | |
| 2022-12-02 | Sale | Ordentlich Peter | Chief Scientific Officer | 17,200 0.0272% | $25.05 | $430,936 | -16.75% | |
| 2022-10-06 | Sale | Katkin Keith | director | 20,782 0.0325% | $25.90 | $538,273 | -17.82% | |
| 2022-10-06 | Sale | Metzger Michael A | Chief Executive Officer | 16,231 0.0248% | $25.29 | $410,508 | -17.82% | |
| 2022-10-04 | Sale | Katkin Keith | director | 137 0.0002% | $25.00 | $3,425 | ||
| 2022-10-04 | Sale | Metzger Michael A | Chief Executive Officer | 1,280 0.002% | $25.02 | $32,026 | ||
| 2022-09-15 | Sale | Podlesak Dennis | director | 66,840 0.1085% | $24.20 | $1.62M | -11.15% |
Insider Historical Profitability
| Meury William | director | 48000 0.0597% | $19.88 | 0 | 1 | |
| Morrison Briggs | director | 17836 0.0222% | $19.88 | 4 | 18 | +43.88% |
| Goldan Keith A. | Chief Financial Officer | 52623 0.0033% | $19.88 | 1 | 1 | |
| ROYSTON IVOR | director | 750545 0.9329% | $19.88 | 1 | 0 | <0.0001% |
| Podlesak Dennis | director | 75763 0.0942% | $19.88 | 1 | 1 | +23.96% |
| Katkin Keith | director | 32000 0.0398% | $19.88 | 0 | 2 | |
| Legault Pierre | director | 32000 0.0398% | $19.88 | 0 | 4 | |
| Metzger Michael A | 17659 0.022% | $19.88 | 0 | 21 | ||
| Egros Fabrice | 16000 0.0199% | $19.88 | 0 | 4 | ||
| Meyers Michael L. | SVP, Chief Medical Officer | 15666 0.0195% | $19.88 | 3 | 0 | +40.96% |
| Nolte Alexander | 0 0% | $19.88 | 0 | 1 | ||
| Ordentlich Peter | 0 0% | $19.88 | 0 | 9 |
Institutional Investor Ownership
| BlackRock | $179.75M | 8.89 | 7.55M | +7.65% | +$12.78M | <0.01 | |
| Wellington Management Company | $176.99M | 8.75 | 7.44M | -1.96% | -$3.54M | 0.03 | |
| Kynam Capital Management Lp | $134.71M | 6.66 | 5.66M | 0% | +$0 | 1.7 | |
| The Vanguard Group | $117.26M | 5.8 | 4.93M | +13.65% | +$14.08M | <0.01 | |
| State Street | $114.71M | 5.67 | 4.82M | -3.92% | -$4.68M | 0.01 | |
| Avoro Capital Advisors Llc | $100.49M | 4.97 | 4.22M | 0% | +$0 | 1.2 | |
| Eversept Partners LP | $74.57M | 3.69 | 3.13M | -7.39% | -$5.95M | 5.61 | |
| T Rowe Price Investment Management Inc | $58.53M | 2.89 | 2.46M | -9.29% | -$6M | 0.04 | |
| Avidity Partners Management Lp | $57.42M | 2.84 | 2.41M | -38.92% | -$36.59M | 2.08 | |
| Point72 Asset Management | $49.19M | 2.43 | 2.07M | -27.09% | -$18.27M | 0.09 | |
| Marshall Wace | $48.36M | 2.39 | 2.03M | -3.32% | -$1.66M | 0.06 | |
| Bvf Inc Il | $44.63M | 2.21 | 1.88M | 0% | +$0 | 0.33 | |
| Morgan Stanley | $43.22M | 2.14 | 1.82M | +9.1% | +$3.6M | <0.01 | |
| Geode Capital Management | $42.34M | 2.09 | 1.78M | +15.86% | +$5.8M | <0.01 | |
| OrbiMed | $41.63M | 2.06 | 1.75M | 0% | +$0 | 0.85 | |
| Bank of America | $39.39M | 1.95 | 1.66M | +68.15% | +$15.96M | <0.01 | |
| Sofinnova | $38.28M | 1.89 | 1.61M | +49.52% | +$12.68M | 0.08 | |
| Woodline Partners LP | $36.75M | 1.82 | 1.54M | +<0.01% | +$1,689.80 | 0.35 | |
| Franklin Templeton Investments | $35.6M | 1.76 | 1.5M | +10.55% | +$3.4M | 0.01 | |
| Goldman Sachs | $31.18M | 1.54 | 1.31M | +4.73% | +$1.41M | 0.01 | |
| Candriam S C A | $24.87M | 1.23 | 1.05M | +2.35% | +$571,200.01 | 0.16 | |
| Aisling Capital Management LP | $24.39M | 1.21 | 1.02M | 0% | +$0 | 8.36 | |
| Iron Triangle Partners LP | $23.16M | 1.15 | 973,057 | New | +$23.16M | 2.4 | |
| Adage Capital Partners Gp L L C | $21.42M | 1.06 | 900,000 | 0% | +$0 | 0.04 | |
| Kingdon Capital Management | $21.3M | 1.05 | 894,993 | +19.93% | +$3.54M | 2.82 | |
| GOLDEN CAPITAL MANAGEMENT LLC | $20.82M | 1.03 | 875,000 | 0% | +$0 | 12.09 | |
| Sphera Fund | $19.35M | 0.96 | 812,964 | +5.17% | +$951,999.99 | 3.2 | |
| Schonfeld Group | $18.7M | 0.92 | 785,644 | +66.64% | +$7.48M | 0.13 | |
| Parkman Healthcare Partners Llc | $18.68M | 0.92 | 784,811 | +6.26% | +$1.1M | 2.31 | |
| Healthcare Of Ontario Pension Plan Trust Fund | $18.56M | 0.92 | 780,000 | 0% | +$0 | 0.06 | |
| Northern Trust | $17.66M | 0.87 | 741,827 | +9.4% | +$1.52M | <0.01 | |
| Susquehanna International Group | $17.52M | 0.87 | 736,148 | +2,917.37% | +$16.94M | 0.02 | |
| Two Sigma | $17.1M | 0.85 | 718,552 | +34.07% | +$4.35M | 0.03 | |
| JPMorgan Chase | $16.24M | 0.8 | 682,464 | -12.61% | -$2.34M | <0.01 | |
| Millennium Management LLC | $16.23M | 0.8 | 681,874 | -27.66% | -$6.21M | 0.01 | |
| DAFNA Capital Management, LLC | $15.7M | 0.78 | 659,574 | -11.18% | -$1.98M | 3.65 | |
| PFM Health Sciences | $15.68M | 0.78 | 658,694 | +10.61% | +$1.5M | 0.43 | |
| Charles Schwab | $15.12M | 0.75 | 635,207 | +10.08% | +$1.38M | <0.01 | |
| Federated Hermes | $12.82M | 0.63 | 538,714 | New | +$12.82M | 0.03 | |
| Ensign Peak Advisors Inc | $12.25M | 0.61 | 514,852 | 0% | +$0 | 0.02 | |
| Ameriprise Financial | $12.17M | 0.6 | 511,501 | +1.08% | +$130,703.33 | <0.01 | |
| Nantahala Capital Management Llc | $11.07M | 0.55 | 465,259 | +27.38% | +$2.38M | 1.14 | |
| Two Sigma Advisers LP | $10.85M | 0.54 | 455,852 | +200.99% | +$7.24M | 0.02 | |
| Algert Global LLC | $10.13M | 0.5 | 425,673 | -19.4% | -$2.44M | 0.4 | |
| Palo Alto Investors Lp | $9.64M | 0.48 | 405,193 | -14.26% | -$1.6M | 1.09 | |
| Saturn V Capital Management Llc | $9.47M | 0.47 | 397,997 | -23.29% | -$2.88M | 3.8 | |
| Granahan Investment Management | $9.45M | 0.47 | 396,878 | +23.67% | +$1.81M | 0.33 | |
| Nuveen | $9.35M | 0.46 | 392,686 | -37.07% | -$5.51M | <0.01 | |
| Rafferty Asset Management Llc | $8.88M | 0.44 | 373,238 | -7.47% | -$717,403.37 | 0.03 | |
| Soleus Capital Management, L.P. | $8.78M | 0.43 | 369,000 | -28.21% | -$3.45M | 0.08 |